Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
Incretin-based therapies with glucagon-like peptide-1 receptor agonists (GLP-1RA) are already established in the treatment of type 2 diabetes (T2D). The development of novel dual- or triple-receptor agonists that bind to the receptors not only for GLP-1 but also to the receptors for glucose-dependent insulinotropic polypeptide (GIP) and/or glucagon is intended to address different metabolic pathways for carbohydrate, lipid, and protein metabolism simultaneously. Dual- and triple-receptor agonists acting via different receptors and postreceptor pathways seem attractive in view of potentially additive or synergistic effects in the treatment of T2D and obesity. Recently, the first approval for a dual-receptor agonist marks an important step in this development. The GIP/GLP-1-receptor agonist tirzepatide was approved for the treatment of T2D by the Food and Drug Administration (FDA) in the USA for once-weekly subcutaneous injections in May 2022 and has just received a positive opinion from the European Medicines Agency (EMA). Tirzepatide dose-dependently leads to clinically significant reductions in glycemic parameters and body weight and has been shown to have stronger effects in reducing these parameters than standard antidiabetic therapy. This article summarizes the current clinical study program and the respective outcomes and highlights further potential indications for tirzepatide in the treatment of obesity and potentially other comorbidities of T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 3×
“Another contraindication is the use of GLP-1RA in patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2 (33, 34, 36).”
BackgroundGuh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 3×
“Frontiers in Endocrinology 09 study at 72 weeks were the percentage change in weight from baseline and a body weight reduction of 5% or more (82).”
BackgroundMethodInfluentialEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726 · cited 1×
“Diabetes accounts for premature mortality and a loss of life expectancy of approximately 6 years due to vascular comorbidities and complications when glucose control is suboptimal (2).”
BackgroundNon-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 5×
“In the SURPASS-2 study, the three doses of tirzepatide (5, 10, and 15 mg once weekly) were tested with the GLP-1RA semaglutide (1 mg once weekly) as a comparator in patients not optimally controlled on monotherapy with metformin (71).”
BackgroundMethodResultInfluentialGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · cited 1×
“While GIP loses its insulinotropic effect in T2D with chronic hyperglycemia, GLP-1 is still able to stimulate insulin secretion (28, 29).”
BackgroundGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 3×
“Another contraindication is the use of GLP-1RA in patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2 (33, 34, 36).”
Background9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“While GIP loses its insulinotropic effect in T2D with chronic hyperglycemia, GLP-1 is still able to stimulate insulin secretion (28, 29).”
BackgroundMENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161 · cited 2×
“Native GLP-1 is not suitable for treatment, since the peptide is degraded rapidly within minutes by the enzyme dipeptidyl-peptidase-IV (DPP-4) (31, 32).”
BackgroundSelf-citationDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“Parenteral administration of pharmacological doses of GLP-1 is able to normalize plasma glucose by stimulating insulin secretion and simultaneously inhibiting glucagon secretion in subjects with T2D and hyperglycemia (30).”
BackgroundRosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080 · cited 3×
“The SURPASS-1 trial investigated the efficacy and safety of the three doses of 5, 10, or 15 mg tirzepatide in drug-naïve patients with T2D who were not sufficiently controlled with a lifestyle intervention with diet and exercise versus placebo (70).”
BackgroundMethodKhan, S. S., Ning, H., Wilkins, J. T., Allen, N., Carnethon, M., Berry, J. D., Sweis, R. N., & Lloyd-Jones, D. M. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.0022 · Cited by 1,072
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021 · cited 1×
“Clinical studies in humans have not been published so far (41, 51).”
BackgroundCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 5×
“The pharmacokinetics in healthy volunteers and patients with T2D are comparable (57).”
BackgroundInfluentialNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 1×
“The so-called incretin effect describes this phenomenon and also explains that orally ingested glucose leads to a higher insulin response than intravenously administered glucose leading to isoglycemic glucose excursions compared to oral glucose (26, 27).”
BackgroundCardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · cited 2×
“Native GLP-1 is not suitable for treatment, since the peptide is degraded rapidly within minutes by the enzyme dipeptidyl-peptidase-IV (DPP-4) (31, 32).”
BackgroundLong-term follow-up after tight control of blood pressure in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Neil, H. A. W., & Matthews, D. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806359 · Cited by 762
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731 · cited 1×
“The so-called incretin effect describes this phenomenon and also explains that orally ingested glucose leads to a higher insulin response than intravenously administered glucose leading to isoglycemic glucose excursions compared to oral glucose (26, 27).”
BackgroundMosenzon, O., Wiviott, S. D., Cahn, A., Rozenberg, A., Yanuv, I., Goodrich, E. L., Murphy, S. A., Heerspink, H. J. L., Zelniker, T. A., Dwyer, J. P., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30180-9 · Cited by 684
Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684 · cited 3×
“A substudy of SURPASS-3 investigated glycemia using continuous glucose monitoring (CGM) (73).”
BackgroundMethodInfluentialLudvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639 · cited 2×
“Hypoglycemia (<54 mg/dl or severe) was reported in five (1%), four (1%), and eight (2%) participants on tirzepatide 5, 10, and 15 mg, respectively, versus 26 (7%) on insulin degludec (54, 72).”
BackgroundMethodGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597 · cited 4×
“In this study, the mortality due to COVID-19 was <1% in the tripeptide arms as well as in the insulin glargine arms, with a numerically lower mortality rate in the tirzepatide group (75).”
BackgroundMethodInfluentialTirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541 · cited 1×
“Imbalance towards the GIP receptor, combined with distinct signaling properties at the GLP-1 receptor, together may account for the promising efficacy of tirzepatide as observed in various cell models, isolated islets, and perfused pancreas (86).”
BackgroundGastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513 · cited 3×
“29), reductions in the transaminase liver enzyme ASAT (r = 0·33), and reductions in body weight (p = 0·34) in the tirzepatide groups (54, 79).”
BackgroundMethodNauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506 · cited 1×
“In healthy volunteers, infusions of GLP-1 and GIP had additive effects on the stimulation of insulin secretion (42).”
BackgroundNauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388 · cited 4×
“TABLE 1 Effects of GIP receptor agonism or antagonism on glycemic control, body weight, and energy balance in animal models of obesity and diabetes (modified according to Campbell and Nauck) (47, 49).”
BackgroundInfluentialClinical Use of DPP-4 Inhibitors
Gallwitz, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00389 · Cited by 374
Self-citationHartman, M. L., Sanyal, A. J., Loomba, R., Wilson, J. M., Nikooienejad, A., Bray, R., Karanikas, C. A., Duffin, K. L., Robins, D. A., & Haupt, A. (2020) · Diabetes Care · doi:10.2337/dc19-1892 · Cited by 351
Tirzepatide cardiovascular event risk assessment: A pre-specified meta-analysis
Sattar, N., McGuire, D. K., Pavo, I., Weerakkody, G. J., Nishiyama, H., Wiese, R. J., & Zoungas, S. (2022) · Nature Medicine · doi:10.1038/s41591-022-01707-4 · Cited by 346 · cited 2×
“A recent meta-analysis of data from seven double-blind randomized controlled trials with tirzepatide lasting at least 26 weeks confirmed the cardiovascular safety of tirzepatide in patients with T2D (77).”
MethodResultNahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323 · cited 1×
“Gastrointestinal side effects observed under cotadutide effects are similar in quality but more severe than those under GLP-1RA treatment (52).”
BackgroundMin, T., & Bain, S. C. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00981-0 · Cited by 285 · cited 1×
“This study program named SURPASS comprises six global, two Japanese, and one Asian-Pacific study (69).”
BackgroundKaragiannis, T., Avgerinos, I., Liakos, A., Del Prato, S., Matthews, D. R., Tsapas, A., & Bekiari, E. (2022) · Diabetologia · doi:10.1007/s00125-022-05715-4 · Cited by 272
Islet α cells and glucagon--critical regulators of energy homeostasis
Campbell, J. E., & Drucker, D. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.51 · Cited by 266 · cited 1×
“glucose homeostasis and administration of pharmacological doses of glucagon in animal models for diabetes or obesity has demonstrated regulatory effects on lipid metabolism, energy expenditure, and food intake (41, 50).”
BackgroundGlucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005
Holst, J. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0107-1 · Cited by 228
Frias, J. P., Nauck, M. A., Van, J., Benson, C., Bray, R., Cui, X., Milicevic, Z., Urva, S., Haupt, A., & Robins, D. A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13979 · Cited by 208
Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: A mini-review
Chavda, V. P., Ajabiya, J., Teli, D., Bojarska, J., & Apostolopoulos, V. (2022) · Molecules · doi:10.3390/molecules27134315 · Cited by 208
GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Holst, J. J., & Rosenkilde, M. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa327 · Cited by 207 · cited 2×
“Due to these findings, GIP did not seem to be a therapeutic option for T2D or obesity (46, 47).”
BackgroundWadden, T. A., Tronieri, J. S., Sugimoto, D., Lund, M. T., Auerbach, P., Jensen, C., & Rubino, D. (2020) · Obesity · doi:10.1002/oby.22726 · Cited by 200 · cited 1×
“2 mg once daily) due to the results of the SCALE study program (37, 38).”
BackgroundWilson, J. M., Nikooienejad, A., Robins, D. A., Roell, W. C., Riesmeyer, J. S., Haupt, A., Duffin, K. L., Taskinen, M., & Ruotolo, G. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14174 · Cited by 164
Wilson, J. M., Lin, Y., Luo, M. J., Considine, G., Cox, A. L., Bowsman, L. M., Robins, D. A., Haupt, A., Duffin, K. L., & Ruotolo, G. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14553 · Cited by 149
Syed, Y. Y. (2022) · Drugs · doi:10.1007/s40265-022-01746-8 · Cited by 144 · cited 10×
“Tirzepatide has a comparable safety profile to GLP-1RA (54, 70).”
BackgroundMethodInfluentialEmerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
Clemmensen, C., Finan, B., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Hofmann, S. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0118-x · Cited by 134
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133 · cited 2×
“TABLE 1 Effects of GIP receptor agonism or antagonism on glycemic control, body weight, and energy balance in animal models of obesity and diabetes (modified according to Campbell and Nauck) (47, 49).”
BackgroundPirro, V., Roth, K. D., Lin, Y., Willency, J. A., Milligan, P. L., Wilson, J. M., Ruotolo, G., Haupt, A., Newgard, C. B., & Duffin, K. L. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab722 · Cited by 113 · cited 2×
“The data on insulin secretion, insulin sensitivity, and glucose homeostasis were confirmed in the phase II clinical study (clinical trials registration number NCT03131687) (62).”
Structure/Activity Characterization of Glucagon‐Like Peptide‐1
Gallwitz, B., Witt, M., Paetzold, G., Morys‐Wortmann, C., Zimmermann, B., Eckart, K., Fölsch, U. R., & Schmidt, W. E. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.1151b.x · Cited by 99 · cited 1×
“Frontiers in Endocrinology 03 structural requirements for GLP-1 and GLP-1/GIP chimeric peptides regarding their affinity towards the GLP-1 receptor in insulinoma cell lines (44, 45).”
BackgroundSelf-citationFinan, B., Clemmensen, C., & Müller, T. D. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.003 · Cited by 81
The incretin/glucagon system as a target for pharmacotherapy of obesity
Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews · doi:10.1111/obr.13372 · Cited by 77 · cited 2×
“Clinical studies in humans have not been published so far (41, 51).”
BackgroundSelf-citationGallwitz, B., Witt, M., Fölsch, U. R., Creutzfeldt, W., & Schmidt, W. E. (1993) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0100259 · Cited by 60 · cited 1×
“They bind to highly selective specific receptors, GLP-1 has a very low affinity towards the GIP receptor and vice versa (43).”
BackgroundSelf-citationA phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes
Furihata, K., Mimura, H., Urva, S., Oura, T., Ohwaki, K., & Imaoka, T. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14572 · Cited by 59
Battelino, T., Bergenstal, R. M., Rodríguez, A., Fernández Landó, L., Bray, R., Tong, Z., & Brown, K. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00077-8 · Cited by 55 · cited 3×
“Tirzepatide treatment was not associated with excess cardiovascular risk (54, 74).”
BackgroundOnce-Weekly Semaglutide for Weight Management: A Clinical Review
Fornes, A., Huff, J., Pritchard, R. I., & Godfrey, M. (2022) · Journal of Pharmacy Technology · doi:10.1177/87551225221092681 · Cited by 50
Liraglutide: clinical pharmacology and considerations for therapy
Sisson, E. M. (2011) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.9.896 · Cited by 49
Gallwitz, B., Witt, M., Morys‐Wortmann, C., Fölsch, U. R., & Schmidt, W. E. (1996) · Regulatory Peptides · doi:10.1016/0167-0115(96)00019-5 · Cited by 46 · cited 1×
“Frontiers in Endocrinology 03 structural requirements for GLP-1 and GLP-1/GIP chimeric peptides regarding their affinity towards the GLP-1 receptor in insulinoma cell lines (44, 45).”
BackgroundSelf-citationStefan, N., Sippel, K., Heni, M., Fritsche, A., Wagner, R. J., Jakob, C. E. M., Preissl, H. T., von Werder, A., Khodamoradi, Y., Borgmann, S., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.875430 · Cited by 28 · cited 1×
“Young and middle-aged adult patients with all three of the above risk parameters had a similar adjusted increased risk of mortality as older (56–75 years) nonobese and metabolically healthy patients (87).”
BackgroundSelf-citationThe ongoing evolution of basal insulin therapy over 100 years and its promise for the future
Retnakaran, R. R., & Zinman, B. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14552 · Cited by 27
Liraglutide: A glucagon-like peptide-1 agonist for chronic weight management
Manigault, K., & Thurston, M. M. (2016) · The Consultant Pharmacist · doi:10.4140/tcp.n.2016.685 · Cited by 25 · cited 1×
“2 mg once daily) due to the results of the SCALE study program (37, 38).”
BackgroundPersonality Features in Obesity
Buratta, L., Pazzagli, C., Delvecchio, E., Cenci, G. I., Germani, A., & Mazzeschi, C. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2020.530425 · Cited by 10
Cited by
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
“In this perspective, the possibilities of double (GLP-1 and GIP or GLP1 and glucagon) or triple (GLP-1, GIP and glucagon) receptor agonism [147,148] are the issue of recent research.”
BackgroundThe intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Bany Bakar, R., Reimann, F., & Gribble, F. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00830-y · Cited by 144
“…processes can be targeted therapeutically; for example, glucagon-like peptide 2 (GLP2) receptor agonists are used for treatment of short bowel syndrome 9,10 , and glucagon-like peptide 1 (GLP1) receptor agonists are used in the management of type 2 diabetes mellitus (T2DM) and obesity 11,12 .”
BackgroundStefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142
Tirzepatide: A Systematic Update
Forzano, I., Varzideh, F., Avvisato, R., Jankauskas, S. S., Mone, P., & Santulli, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314631 · Cited by 118
Min, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 132
“3,28 31 Several clinical trials and reviews have been conducted to clarify the safety and effectiveness of GLP-1 RAs and a dual GLP-1/GIP RA.”
Metadata
- Authors
- Gallwitz, B.
- Affiliations
- University of Tübingen (DE)
- Corresponding author
- Gallwitz, Baptist
- ORCID
- Gallwitz, Baptist
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2022-10-13
- Volume
- 13
- Pages
- 1004044-1004044
- ISSN
- 1664-2392 (ISSN-L)
- PMC
- PMC9606350
- OpenAlex
- W4306155811
- Cited by
- 81
- References
- 76
- Citations by year
- 2026: 18 · 2025: 22 · 2024: 23 · 2023: 17 · 2022: 1
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- tirzepatide, GIP/GLP-1 receptor agonist, type 2 diabetes, obesity, dual receptor agonist, incretin-based therapy, glycemic control, weight loss, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, glucagon receptor, antidiabetic drug development
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Diabetes Mellitus, Type 2, Humans, Obesity, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.